BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 27466354)

  • 1. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
    Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
    Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
    Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
    Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.
    Belisario DC; Akman M; Godel M; Campani V; Patrizio MP; Scotti L; Hattinger CM; De Rosa G; Donadelli M; Serra M; Kopecka J; Riganti C
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
    Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
    Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
    Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
    Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
    J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhein reverses doxorubicin resistance in SMMC-7721 liver cancer cells by inhibiting energy metabolism and inducing mitochondrial permeability transition pore opening.
    Wu L; Cao K; Ni Z; Wang S; Li W; Liu X; Chen Z
    Biofactors; 2019 Jan; 45(1):85-96. PubMed ID: 30496631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
    Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
    Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
    Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
    Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
    Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells.
    Liu Y; Liu X; Yang S
    Biol Pharm Bull; 2021 Jun; 44(6):861-868. PubMed ID: 33828027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling.
    Hu T; Fei Z; Su H; Xie R; Chen L
    Toxicol Appl Pharmacol; 2019 May; 371():55-62. PubMed ID: 30974157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.
    Kamata E; Kawamoto T; Ueha T; Hara H; Fukase N; Minoda M; Morishita M; Takemori T; Fujiwara S; Nishida K; Kuroda R; Kurosaka M; Akisue T
    Anticancer Res; 2017 Nov; 37(11):6097-6106. PubMed ID: 29061790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
    Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
    Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis.
    Ji Y; Liu J; Zhu W; Ji J
    Cancer Biother Radiopharm; 2023 Nov; 38(9):585-595. PubMed ID: 33351694
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
    Dieudonné FX; Marion A; Marie PJ; Modrowski D
    J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
    Rathore K; Cekanova M
    Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.